A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Global Clinical Leader
Daiichi Sankyo
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
482 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Centro Oncologico Riojano Integral
Capital, La Rioja Province, Argentina
- Instituto de Oncología de Rosario
Rosario, Santa Fe Province, Argentina
- Sanatorio Británico de Rosario
Rosario, Santa Fe Province, Argentina
- Coiba
Buenos Aires, Argentina
- Instituto Alexander Fleming
Caba, Argentina
- Cer San Juan
San Juan, Argentina
- Royal Adelaide Hospital
Adelaide, Australia
- Chris O Brien Lifehouse
Camperdown, Australia
- Monash Health
Clayton, Australia
- Austin Hospital- Olivia Newto-John Cancer and Wellness Centre
Heidelberg, Australia
- Peter Maccallum Cancer Centre
Melbourne, Australia
- Breast Cancer Research Centre - Wa
Nedlands, Australia
- Genesis Care Northern Cancer
Saint Leonards, Australia
- St John of God Hospital - Bendat Family Comprehensive Cancer Centre (bfccc)
Subiaco, Australia
- Southern Medical Day Care Centre
Wollongong, Australia
- Antwerp University Hospital
Edegem, Antwerpen, Belgium
- Uz Gent
Ghent, O. VL., Belgium
- Algemeen Ziekenhuis Az Klina - Borstkliniek
Brasschaat, Belgium
- Cliniques Universitaires Saint-Luc
Brussels, Belgium
- Institut Jules Bordet Brussels Belgium
Brussels, Belgium
- Uz Leuven - Campus Gasthuisberg
Leuven, Belgium
- Chu Liege
Liège, Belgium
- Gza Hospitals Campus Sint- Augustinus
Wilrijk, Belgium
- Hospital Sirio-Libanes Hsl - Centro de Oncologia - Brasilia
Brasília, Federal District, Brazil
- Hospital Erasto Gaertner
Curitiba, Paraná, Brazil
- Fundação Universidade de Caxias Do Sul Instituto de Pesquisas Em Saúde Ips-Ucs
Caxias do Sul, Rio Grande do Sul, Brazil
- Hospital Sao Lucas Pucrs
Porto Alegre, Rio Grande do Sul, Brazil
- Fundacao Pio Xii-Hospital de Cancer de Barretos
Barretos, São Paulo, Brazil
- Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia
Santo André, São Paulo, Brazil
- Hospital de Base de Sao Jose Do Rio Preto
São José do Rio Preto, São Paulo, Brazil
- Inca - Instituto Nacional Do Cancer / Hospital Do Cancer Hciii
Rio de Janeiro, Brazil
- Instituto Do Cancer Do Estado de Sao Paulo (icesp)
São Paulo, Brazil
- Tom Baker Cancer Centre
Calgary, Alberta, Canada
- the Ottawa Hospital Cancer Centre
Ottawa, Ontario, Canada
- Chum
Montreal, Quebec, Canada
- Ciussss de L'Est-de-L'Ile-de-Montréal - Installation Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
- Jewish General Hospital Segal Cancer Centre
Montreal, Quebec, Canada
- Mcgill University Health Centre - Cedars Cancer Centre
Montreal, Quebec, Canada
- Chu de Quebec - Hopital Du Saint-Sacrement
Québec, Quebec, Canada
- Hospital Clinico Universidad de Chile
Santiago, RM, Chile
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 4 Dec 2020
- Primary completion
- 2 Jul 2025
- Completion
- 20 Jun 2028
- Last update posted
- 15 May 2026
- Registered enrollment
- 1,600
- Registry id
- NCT04622319
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.